Skip to main content
Caplight Logo









Leucid Bio

Leucid Bio

Private
LondonHealthcare & Life Scienceshttps://www.leucid.com/

Last Round

Series A

Extension

Feb 1, 2025

Total Funding Raised

$25.35M

Company Overview

Leucid Bio is a biotechnology company that develops next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T therapycell therapysolid tumor oncologybiotechnologycancer immunotherapytumor microenvironmentdrug discoveryclinical-stage biotechnext-gen CAR-Tbiopharma R&Dclinical trialsprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Leucid Bio Comparables

Compare Leucid Bio with similar companies based on industry and business-model similarity.

Leucid Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Inceptor Bio
88%
Innovative Cellular Therapeutics
86%
AffyImmune Therapeutics
84%

Leucid Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 1, 2025
Series AOct 21, 2021

Key People

Founding team and executive leadership

Filippo Petti

Chief Executive Officer

Executive Team

Leucid Bio Investors

Notable investors and investment history

Leucid Bio investors
InvestorRounds
Epidarex CapitalSeries A Extension, Series A
2invest AGSeries A, Series A Extension
Vulpes Investment ManagementSeries A
Sofinnova PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 1, 2025

    $9.5M round led by 2invest AG and Epidarex Capital

  • Oct 21, 2021

    $16M round led by Epidarex Capital and Vulpes Investment Management.

Leucid Bio Filings

Explore SEC and related filing metadata, where available.

Leucid Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Leucid Bio's valuation, stock price, and market status.

Is Leucid Bio a public or private company?

Leucid Bio is a private company.

What is the current stock price of Leucid Bio?

Leucid Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Leucid Bio worth (valuation)?

Valuation information for Leucid Bio is not publicly available.

Can I buy Leucid Bio stock?

Leucid Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Leucid Bio's last funding round?

Leucid Bio's most recent funding round was Series A Extension on February 1, 2025.

Who are the main investors in Leucid Bio?

Key investors in Leucid Bio include Epidarex Capital, 2invest AG, Vulpes Investment Management.

Will Leucid Bio IPO soon?

No public IPO plans have been announced for Leucid Bio.

How can I track Leucid Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Leucid Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range15
Year Founded2014
Last FundingFeb 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?